Mary C. Birmingham

Pediatrics
525 E 68th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin.

Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin.

Journal: JACC. Heart failure
Published: September 20, 2023

Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.

Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.

Journal: Circulation
Published: May 16, 2023

Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure.

Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure.

Journal: JACC. Heart failure
Published: February 28, 2023

Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial.

Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial.

Journal: Journal of cardiac failure
Published: August 17, 2022

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.

Journal: Nature medicine
Published: September 06, 2021

Novel Trial Design: CHIEF-HF.

Novel Trial Design: CHIEF-HF.

Journal: Circulation. Heart failure
Published: March 16, 2021

Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial.

Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial.

Journal: American heart journal
Published: July 17, 2020

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Journal: The New England journal of medicine
Published: December 14, 2016
Showing 1-8 of 8

Last Updated: 09/26/2026